Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 12

AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease

Sep 30, 2026
AbbVie has received U.S. Food and Drug Administration (FDA) approval for JUVMO (tavapadon), a once-daily oral treatment for adults with Parkinson’s disease. The approval makes JUVMO the…
Read More...

Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline

Sep 30, 2026
Tolerance Bio has entered into an exclusive licensing agreement with Tanabe Pharma Corporation to develop and commercialize TLB-33, a clinical-stage anti-IL-33 monoclonal antibody,…
Read More...

Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Sep 30, 2026
While splice modulation has produced some of the field's most significant successes to date, researchers are increasingly exploring direct RNA binding as a route to achieving…
Read More...

Daiichi Sankyo and MSD Withdraw Ifinatamab Deruxtecan FDA Filing

Sep 28, 2026
Daiichi Sankyo and MSD have voluntarily withdrawn their U.S. Biologics License Application (BLA) for ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer…
Read More...

FDA Clears TriSalus TriNav Advance for Liver Embolization

Sep 25, 2026
TriSalus Life Sciences has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav Advance, a new device designed to expand pressure-enabled drug delivery options…
Read More...

Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration

Sep 25, 2026
Turbine and Daiichi Sankyo have expanded their collaboration to use virtual biology and computational experiments to support the discovery and development of antibody-drug conjugates…
Read More...

Genialis and Inventia Join Forces to Improve Pancreatic Cancer Research

Sep 25, 2026
Genialis and Inventia Life Science have announced a collaboration aimed at improving how new pancreatic cancer treatments are tested and matched to patients who may benefit from them.…
Read More...

FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik

Sep 25, 2026
Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes.…
Read More...

Boehringer Ingelheim Pledges $5 Million for Global Obesity Care

Sep 24, 2026
Boehringer Ingelheim and the WHO Foundation have launched a three-year collaboration to strengthen obesity care and metabolic health services in resource-limited settings. Under the…
Read More...

Enveda Raises $311 Million to Advance AI-Discovered Medicines

Sep 24, 2026
Enveda has raised $311 million in a Series E financing round to advance its pipeline of medicines discovered using artificial intelligence and natural biological chemistry. The…
Read More...
Previous 1 … 10 11 12 13 14 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.